| Cas No.: | 5108-96-3 |
| Chemical Name: | Pyrrolidine dithiocarbamic acid |
| Synonyms: | 1-Pyrrolidinecarbodithioic acid, ammoniumsalt;Ammonium pyrrolidinedithiocarbamate~APDC;APDC;APDTC;Pyrrolidinedithiocarbamate;ammonium pyrrolidine-1-carbodithioate;Ammonium tetramethylenedithiocarbamate;PYRROLIDINE-N-DITHIOCARBAMIC ACID AMMONIUM SALT;PYRROLIDINECARBODITHIOIC ACID AMMONIUM SALT;PYRROLIDINEDITHIOCARBAMATE AMMONIUM;PYRROLIDINEDITHIOCARBAMATE, AMMONIUM DERIVATIVE;PYRROLIDINEDITHIOCARBAMATE AMMONIUM SALT;PYRROLIDINEDITHIOCARBAMIC ACID AMMONIUM SALT;PYRROLIDINE-1-DITHIOCARBOXYLIC ACID AMMONIUM SALT;Ammonium pyrrolidinedithiocarbamate;Ammonium 1-Pyrrolidinecarbodithioate [Reagent for Atomic Absorption Analysis];Ammonium 1-pyrrolidinedithiocarbamate;PDTC (PDC, APDC, Pyrrolidinedithiocarbamate Ammonium);Pyrrolidinedithiocarbamate (ammonium);1-PYRROLIDINECARBODITHIOIC ACID;1-Pyrrolidinecarbodithioic acid ammonium salt,APDC,Ammonium pyrrolidinecarbodithioate;1-Pyrrolidinedithiocarboxylic acid ammonium salt;Ammonium 1-Pyrrolidinecarbodithioate;Ammonium pyrrolidine;Ammonium Pyrrolidine-N-dithiocarbamate;Ammoniumpyrrolidinedithiocarb;APCD;APDC AMMONIUM SALT;APDTC AMMONIUM SALT;PDC;PDTC;Pyrrolindinedithiocarbamate ammonium;1-Pyrrolidinecarbodithioic Acid Ammonium Salt;Pyrrolidine dithiocarbamate;Pyrrolidine-1-carbodithioic acid;Pyrrolidine dithiocarbamic acid;Tetramethylenedithiocarbamic acid;Pyrrolidine-N-carbodithioic acid;Ammonium pyrrolidine dithiocarbamate;1-Pyrrolidinecarbodithioic acid, ammonium salt;C5H9NS2;NSC298194;ammonium tetramethylene dithiocarbamate;NCIOpen2_00 |
| SMILES: | S([H])C(N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H])=S |
| Formula: | C5H9NS2 |
| M.Wt: | 147.2617 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Pyrrolidinedithiocarbamate ammonium is a selective NF-κB inhibitor. |
| In Vivo: | The DSS+pyrrolidinedithiocarbamate ammonium-treated groupII exhibits suppression of shortening of intestinal length and reduction of DAI score. Activated NF-κB level and IL-1β and TNF-α levels are significantly lower in DSS+pyrrolidinedithiocarbamate ammonium-treated groupII. These findings suggest that suppression of NF-κB activity by pyrrolidinedithiocarbamate ammonium can delay the healing of mucosal tissue defects (erosions or ulcers) arising from inflammation, but that it can strongly suppress the expression of inf-lammatory cytokines (IL-1β and TNF-α), resulting in significant alleviation of colitis. pyrrolidinedithiocarbamate ammonium is useful for the treatment of ulcerative colitis[2]. |
| In Vitro: | Pretreatment of cells with pyrrolidinedithiocarbamate (3-1000 μM) dose-dependently attenuate IL-8 production. Furthermore, pyrrolidinedithiocarbamate (100 μM) suppresses the accumulation of IL-8 mRNA. Pyrrolidinedithiocarbamate inhibits the activation of NF-κB, because pyrrolidinedithiocarbamate suppresses both NF-κB DNA binding and NF-κB-dependent transcriptional activity. NF-κB inhibition with pyrrolidinedithiocarbamate decrease IL-8 production by intestinal epithelial cells[1]. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
